Hormonal
Weekly administration of semaglutide (2.4 mg) and tirzepatide (15 mg) produces substantially greater weight loss (9.6% and 13.1% respectively) compared to pre-existing anti-obesity medications (approx. 5% weight reduction).
If you have type 2 diabetes and obesity, current guidelines suggest trying lifestyle changes first. If that fails, newer injectable medications like semaglutide (2.4 mg weekly) or tirzepatide (15 mg weekly) are significantly more effective at reducing body weight (around 10-13%) than older oral or injectable options (around 5%). These require a prescription and gradual dose titration to manage side effects.
In contrast to the modest efficacy of pre-existing AOMs, two newly developed, weekly-administered injectable drugs, semaglutide and tirzepatide, exhibited outstanding weight-loss effects in a series of multinational randomized phase III trials.
Why this rating
Based on multiple multinational randomized phase III trials (STEP 2, SURPASS-1, SURPASS-2).
Source
The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?
Han Na Jung et al. · Journal of Obesity & Metabolic Syndrome · 2022
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →